Verrica Posts $5M Q1 Revenue; YCANTH Units Rise 51.3% YoY and Launch in Japan
VRCA•Verrica reported Q1 revenue of $5.0M, driven by $4.3M in YCANTH sales, up 16.2% sequentially while 15,302 dispensed applicator units rose 12.1% QOQ and 51.3% YoY. The company exceeded 100,000 cumulative YCANTH units, launched in Japan via Torii, and reached over 50% enrollment in its Phase 3 common warts trial.
1. Q1 2026 Financial Results
Verrica recorded total revenue of $5.0 million in the first quarter of 2026, including $4.3 million in net product revenue from YCANTH, marking a 16.2% sequential revenue increase and a 25.4% rise year-over-year. Dispensed applicator units reached 15,302, up 12.1% from the prior quarter and 51.3% year-over-year.
2. YCANTH Market Growth & Expansion
Since launch, YCANTH use has exceeded 100,000 dispensed applicator units. The commercial launch in Japan through Torii Pharmaceutical represents its first ex-U.S. market, supporting broader international adoption.
3. Clinical Pipeline Progress
Enrollment in the first global Phase 3 common warts trial has surpassed 50% of the target, with the second trial set to begin in the U.S. and Japan in mid-2026. The company is also advancing preparations for Phase 3 evaluation of VP-315 in basal cell carcinoma.
